Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca PLC Add to portfolio

LON100:AZN, Sep 30, 02:53 UTC

Latest LON100:AZN News

Filter your feed

Apply Filter

Thursday, February 06


News

Deutsche Bank Appointed as Successor Depositary Bank for the NYSE-Listed American Depositary Receipt Program of AstraZeneca PLC

AZN AZN +1 more AZN AZN DBK

Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt Program of AstraZeneca PLC (NYSE: AZN). AstraZeneca is a global, science-led biopharmaceutical company focusing on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in the therapy areas of Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in more than 100 countries.*. "We are pleased to have been appointed as successor depositary bank for the AstraZeneca PLC American Depositary Receipt program, which is one of the largest and most liquid in the world," said Daniel Clark, Global Head of Depositary Receipts at Deutsche Bank. In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

Read Full Details

Topics:
  • Business
  • Financial
News

Pharma firm AstraZeneca to plant 25m trees

AZN AZN

A multinational pharmaceutical company has pledged to plant 25 million trees somewhere in Australia, though who will do the digging has yet to be decided. British-based AstraZeneca plans to plant 50 million trees in the Asia Pacific region over the next five years in an ambitious project to offset its carbon emissions. Promised last month at the World Economic Forum in Davos, Switzerland, the reforestation is part of the company's commitment to be carbon neutral by 2025, and carbon negative - removing more carbon than it emits - in a decade. They are also in town to announce a $200 million investment in AstraZeneca's western Sydney manufacturing facility which, the company says, will increase its exports to $4.4 billion during the next four years.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

AstraZeneca commits $200m to Sydney plant boosted by Chinese demand

AZN AZN

Feb 7, 2020 — 12.00am. AstraZeneca has committed $200 million for expansion to the British-Swedish multinational pharma group's manufacturing facility in Sydney, creating 250 jobs and increasing exports to $4.4 billion over the next four years. The investment in the North Ryde site bucks the trend of pharmaceutical manufacturers moving production offshore and follows a $100 million investment announced in 2017 by the company, which has operated in Australia for more than 60 years. AstraZeneca – which posted about $US22 billion ($32.5 billion) in global sales in 2018 – is the largest manufacturer and exporter of pharmaceuticals in the country, making drugs like Pulmicort Respules for the treatment of asthma. Global chief Pascal Soriot said the facility expansion is supported by strong growth in the region, in particular China. Mr Soriot said AstraZeneca exports about $1.1 billion from Australia every year, and ships 1600 containers from Port Botany.

Read Full Details

Story Sources

afr.com afr.com
Topics:
  • Business
  • Financial
  • Science

Wednesday, January 29


News

How safe is the Astrazeneca dividend payment (LON:AZN)?

AZN AZN

29 January 2020, 06:50 UTC. Astrazeneca (LON:AZN) is a large cap Pharmaceuticals operator focused on the discovery and development of products, which are then manufactured, marketed and sold. For the nine months ended 30 September 2019, AstraZeneca plc revenues increased 13% to $17.72B but net income decreased 9% to $1.02B. The group pays out an attractive rolling dividend yield of 2.79%, which is forecast to rise by 1.19% over the next year. Poor dividend cover means that a small decline in earnings could consign your dividend payment to the scrap heap. Take a look and see if any of the qualifying stocks might be worthy of further research. As for Astrazeneca (LON:AZN), you can find a wealth of financial data on the group's StockReport, including information on the group's past and forecast dividend payments. If you’d like to discover more about dividend investing, you can read our free ebook: How to Make Money in Dividend Stocks.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment

Monday, January 27


News

AstraZeneca's Brilinta Beats Aspirin in Trial for Reducing Stroke Chances

AZN AZN

Jan 27, 2020 3:21PM EST. AstraZeneca's Brilinta Beats Aspirin in Trial for Reducing Stroke Chances | NASDAQ. AstraZeneca (NYSE: AZN) announced that its blood thinner drug Brilinta met its primary endpoint in a late-stage trial. The phase 3 Thales study, which featured over 11,000 patients, tested whether the two drugs taken together could reduce the chance of stroke in patients that already had a previous stroke. "While an expected increase in bleeding was observed, the findings from THALES showed that Brilinta, in combination with aspirin, reduced the risk of potentially devastating events," said Dr. Clay Johnson, lead investigator of the trial. AstraZeneca plans to present the full data in an upcoming medical meeting, although it wasn't specified which one. Brilinta was first approved by the Food and Drug Administration (FDA) in 2011 to reduce the chance of heart attacks in patients with acute coronary syndrome. Since then, the drug has received expanded approval for long-term use in patients at high risk of heart attacks.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial
News

AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca

AZN AGN

AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca | NASDAQ. Some unlikely good Samaritans are going out of their way to help AbbVie(NYSE: ABBV) and Allergan(NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. To appease antitrust regulators, AstraZeneca(NYSE: AZN) will take back control of an experimental psoriasis drug, and Nestle will acquire a gastrointestinal medication from Allergan. Allergan was developing a monoclonal antibody that inhibits interleukin 23 (IL-23) called brazikumab for the treatment of Crohn's disease and ulcerative colitis. Zenprep is a collection of pancreatic enzymes that is especially useful for cystic fibrosis (CF) patients. Since Nestle already markets nutritional therapies for CF and a wide range of other disorders, Zenprep should fit comfortably in its portfolio.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial
  • Technology
News

Can the AstraZeneca share price hold up after a failed drug trial?

AZN AZN

It’s a fact of the pharmaceutical business that not all drug trials result in a promising product, unfortunately for pharmaceutical companies, shareholders and most importantly patients. A failed drug trial, as much as investors may not like it from a financial standpoint, scientifically is almost as valuable as a successful one – the trial did its job. It’s in this light that news this month from AstraZeneca (LSE: AZN) saying the company will be writing-down $100m after trials of its heart disease drug Epanova were “disappointing”, must be taken. This is, of course, the growth of cheap, generic versions of branded drugs, particularly after the patents end, and particularly in China. While AstraZeneca has not been immune to these troubles, it has managed to offset much of the damage through working with local hospitals and the government in China to help secure fair prices for its treatments. So to answer the title question of this article, I think the failed trial will by no means have a detrimental impact on Astra shares. As I said earlier, the aim of the trial was to see if this drug could work or not in a specific case – it couldn’t, and so the trial actually did what it was supposed to.

Read Full Details

Topics:
  • Business
  • Health
News

AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

AZN AZN +1 more AZN AZN AGN

AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys. ZURICH (Reuters) - U.S. drugmaker AbbVie's <ABBV.N> $63 billion tie-up with Allergan <AGN.N> is getting help from Nestle <NESN.S> and AstraZeneca <AZN.L> buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Nestle Chief Executive Mark Schneider, who also gets Allergan's Viokace, another pancreatic enzyme product, in Monday's deal, is bulking up on nutrition products that combine properties of medicine and food as the Swiss company expands in areas where growth may outpace its mainstream food business.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Allergan To Sell Brazikumab To AstraZeneca, Zenpep To Nestle Under AbbVie Merger

AZN AZN +2 more AZN AZN ABBV AGN

(RTTNews) - Allergan plc (AGN), which is in deal to be bought by AbbVie (ABBV), announced Monday that it has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) to AstraZeneca (AZN, AZN.L) and Nestle SA (NSRGY.PK, NSTR.L), respectively. The agreements are in conjunction with the ongoing regulatory approval process for AbbVie's acquisition of Allergan to create Allergan Aesthetics. The closings of the acquisitions of brazikumab and Zenpep are contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, closing of AbbVie's pending acquisition of Allergan and the satisfaction of other customary closing conditions. AstraZeneca will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights. Further, Swiss food giant Nestle will acquire and take full operational ownership of gastrointestinal medication Zenpep upon closing the transaction with customary transition support from Allergan.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, January 22


News

England Officially Rejects AstraZeneca's Lung Cancer Drug

AZN AZN

One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive approval as the first line of defense for patients with EGFR-positive non-small cell lung cancer -- about 10% of all lung cancer patients. Clinical data has shown that Tagrisso can delay cancer growth for almost 19 months, in comparison to the 10 months that a pair of rival drugs were able to demonstrate. However, NICE found the drug to be too expensive relative to its effectiveness, costing 5,770 pounds ($7570) for a 30-day supply. "The cost-effectiveness estimates vary from slightly below to above the range considered to be a cost-effective use of NHS resources," read an official statement from NICE.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial